Curis (NASDAQ:CRIS) Posts Quarterly Earnings Results, Beats Expectations By $0.13 EPS

Curis (NASDAQ:CRIS) issued its quarterly earnings data on Thursday. The biotechnology company reported ($0.49) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.62) by $0.13, Zacks reports. The company had revenue of $3.18 million for the quarter, compared to the consensus estimate of $2.86 million.

Curis Stock Down 10.3%

CRIS traded down $0.15 during trading on Friday, hitting $1.31. The company’s stock had a trading volume of 233,192 shares, compared to its average volume of 94,923. The firm has a market capitalization of $16.37 million, a P/E ratio of -0.27 and a beta of 3.88. Curis has a twelve month low of $1.02 and a twelve month high of $4.70. The stock’s fifty day moving average price is $1.61 and its 200-day moving average price is $1.85.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Curis stock. Maverick Capital Ltd. increased its stake in shares of Curis, Inc. (NASDAQ:CRIS) by 7.8% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 681,381 shares of the biotechnology company’s stock after acquiring an additional 49,554 shares during the quarter. Maverick Capital Ltd. owned approximately 5.45% of Curis worth $1,472,000 at the end of the most recent quarter. 29.97% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Curis in a report on Wednesday, October 8th. One analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of “Hold” and a consensus target price of $17.00.

About Curis

Curis, Inc, a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single arm expansion trial in patients with relapsed or refractory, or R/R, AML and high-risk myelodysplastic syndromes.